Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

830 breast cancer survivors share their quality of life after treatment

NCT ID NCT03859453

Knowledge-focused Sponsor: European Organisation for Research and Treatment of Cancer - EORTC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study followed 830 women who had early or locally advanced breast cancer and finished their main treatment (except hormone therapy). The goal was to understand their health-related quality of life using several questionnaires. No new treatment was tested; instead, researchers gathered information to improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

830 people

The number who actually took part.

Started

Oct 2020

Finished

Aug 2025

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

EBC and LABC cancer patients after primary treatment attending participating hospitals for routine follow-up.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically proven Early Breast Cancer (EBC) and Locally Advanced Breast Cancer (LABC) patients who have completed their primary treatment (except endocrine therapy), between 12 months and 36 months after the diagnosis. * Disease-free without any evidence of relapse * Age ≥ 18 years. * Ability to understand and fill out questionnaires. * Written informed consent. Exclusion Criteria: * Metastatic breast cancer (defined as secondary spread to other organs, such as bones, lung, liver, mediastinal lymph nodes) or DCIS. * Other cancer diagnosis in the past 5 years except non-melanotic skin cancer or cervical intraepithelial neoplasia. * Male breast cancer. * Patients on maintenance therapy (other than endocrine therapy). * Patients participating in interventional clinical studies with Quality of Life as primary endpoint. * Any psychological (including preexisting psychiatric disorders), familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Assistance Publique Hopitaux Paris - Assistance Publique - Hopitaux de Paris - Hopital Tenon

    Paris, De, France

  • Azienda Ospedaliero-Universitaria Careggi

    Florence, Italy

  • Barts Health NHS Trust - St. Bartholomew'S Hospital

    London, United Kingdom

  • C.H.U. Sart-Tilman

    Liège, Belgium

  • CHU Saint Pierre - CHU Saint-Pierre-Site Porte de Hal

    Brussels, Belgium

  • CHU-UCL Namur - CHU Site Sainte-Elisabeth-UCL Namur

    Namur, Belgium

  • Clinica Universidad de Navarra

    Madrid, Spain

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Complejo Hospitalario de Navarra

    Pamplona, Spain

  • Group Of Private Clinics Hirslanden - Hirslanden Klinik-Tumor Zentrum Aarau

    Aarau, Switzerland

  • Groupe Radiopole Artois - Centre de radiotherapie Marie Curie

    Arras, France

  • HELIOS Kliniken - Helios Klinikum Wuppertal - Klin. Univ. Witten / Herdecke

    Wuppertal, Germany

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Spain

  • IRCCS - Fondazione G. Pascale

    Naples, Italy

  • IRCCS - Istituto Oncologico Veneto

    Padova, Italy

  • King Hussein Cancer Center

    Amman, Jordan

  • Leeds Teaching Hospitals NHS Trust - St. James's University Hospital

    Leeds, United Kingdom

  • Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology

    Warsaw, Poland

  • Medical University Of Gdansk

    Gdansk, Poland

  • Onze Lieve Vrouw Ziekenhuis

    Aalst, Belgium

  • Ospedale Generale Regionale

    Bolzano, Italy

  • Ospedale San Gerardo

    Monza, Italy

  • The Great Poland Cancer Centre

    Poznan, Poland

  • The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

    Amsterdam, Netherlands

  • Tumor and Breast Center ZeTuP St. Gallen

    Sankt Gallen, 9006, Switzerland

  • Universita Di Roma La Sapienza - Universita Degli Studi Di Roma La Sapienza - Ospedale Sant'Andrea

    Roma, Italy

  • Universitaetsklinikum Leipzig-Klinik fuer Strahlentherapie und Radioonkologie

    Leipzig, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.